Cumulatively, we predict that the protein products of the upregulated genes GAS1, COL6A2, CILP, and ASPN may represent ideal therapeutic targets for the treatment of GC, and some background information in this context is already available for GAS1 and COL6A2. Here, ASPN is linked to gastric cancer.